ARCHIVES

ODAC Recommends Iressa Approval As Third-Line Lung Cancer Treatment

This article is from The Cancer Letter archive.

Vol. 28 No. 35 | September 27, 2002

Download PDF Visit The Full Archive

Related Articles

RFAs For Extramural Construction, Mouse Facility Available

March 2, 1990

Stronger Measures Needed To Reduce Conflict of Interest, IOM Report Says

May 1, 2009

Phase III Trial In Recurrent Disease Shows Lower Risk of Progression or Death by 34%

June 28, 2013

In Brief: George Vande Woude Of NCI Named PI for Litton Bionetics Basic Research Contract At Frederick

September 23, 1983

Reinventing NCI: Natural Products Screen Closes; NCI Targets Drug Resistance

December 13, 1996

Peers Puzzled By Herberman’s Stance On Cell Phones While Believers Rally.

August 1, 2008